Clinical Trials Logo

Pulmonary Metastasis clinical trials

View clinical trials related to Pulmonary Metastasis.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05518526 Recruiting - Soft Tissue Sarcoma Clinical Trials

Phase 1b/2 Study of Liposomal Annamycin (L-Annamycin) in Subjects With Previously Treated Soft-Tissue Sarcomas (STS) With Pulmonary Metastases

ANNA-SARC
Start date: August 23, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a multi-centre, open-label, single-arm, 3+3 Phase 1b/ and Phase II. Phase 1b is aimed to determine the maximum-tolerated dose (MTD)/Recommended Phase 2 Dose (RP2D) based on safety reporting. The RP2D is a multifactorial endpoint that considers toxicity as well as additional determinants (e.g. efficacy, pharmacodynamics) to define the optimal Phase 2 dose. Phase 2 will explore the efficacy of L-Annamycin at RP2D for treating soft tissue sarcomas (STS) subjects with lung metastases, for which chemotherapy is considered appropriate.